Wang Lishui, Wang Ding, Zheng Guixi, Yang Yongmei, Du Lutao, Dong Zhaogang, Zhang Xin, Wang Chuanxin
Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan - PR China.
Int J Biol Markers. 2016 Feb 28;31(1):e80-7. doi: 10.5301/jbm.5000177.
Tumor markers CYFRA21-1, CEA, NSE, CA125, pro-GRP and SCC are routinely used for lung cancer. However, there has been no systematic evaluation of these markers in the same cohort. The aim of this study was to evaluate the diagnostic and therapeutic monitoring value of these markers.
The levels of 6 serum tumor markers were measured in 392 patients, including 308 patients with non-small cell lung cancer (NSCLC) and 84 with small cell lung cancer (SCLC), and 116 patients with benign lung diseases and 144 healthy controls. 34 patients were followed up after operation and chemotherapy. Multiple logistic models and receiver operating characteristic (ROC) curves were used to evaluate their diagnostic value.
CEA, NSE, CA125 and pro-GRP in SCLC, and CYFRA21-1 as well as CEA in NSCLC, were higher than those in control groups. The level of CEA and CA125 were related to the clinical stages of NSCLC. Pro-GRP was significantly increased in extensive disease (ED) compared with limited disease (LD) in SCLC. CYFRA21-1 was reduced after the third and fifth treatment cycle respectively in patients who undergoing operation and without operation. NSE and pro-GRP were reduced significantly after the second and third treatment cycles, respectively.
CEA, NSE, CA125 and pro-GRP could serve as biomarkers for SCLC, and CEA and CYFRA21-1 could serve as biomarkers for NSCLC. Pro-GRP, CA125 and CEA were related to the clinical stages of lung cancer. CYFRA21-1, NSE and pro-GRP could be used for monitoring the effect of chemotherapy.
肿瘤标志物CYFRA21-1、癌胚抗原（CEA）、神经元特异性烯醇化酶（NSE）、癌抗原125（CA125）、胃泌素释放肽前体（pro-GRP）和鳞状细胞癌抗原（SCC）常用于肺癌诊断。然而，尚未在同一队列中对这些标志物进行系统评估。本研究旨在评估这些标志物的诊断及治疗监测价值。
检测了392例患者的6种血清肿瘤标志物水平，其中包括308例非小细胞肺癌（NSCLC）患者、84例小细胞肺癌（SCLC）患者、116例良性肺疾病患者和144例健康对照者。对34例患者进行了术后及化疗随访。采用多因素逻辑回归模型和受试者工作特征（ROC）曲线评估其诊断价值。
SCLC患者中的CEA、NSE、CA125和pro-GRP，以及NSCLC患者中的CYFRA21-1和CEA，均高于对照组。CEA和CA125水平与NSCLC临床分期相关。SCLC广泛期（ED）患者的pro-GRP水平显著高于局限期（LD）患者。接受手术和未接受手术的患者在分别接受第3个和第5个治疗周期后，CYFRA21-1水平降低。NSE和pro-GRP分别在第2个和第3个治疗周期后显著降低。
CEA、NSE、CA125和pro-GRP可作为SCLC的生物标志物，CEA和CYFRA21-1可作为NSCLC的生物标志物。Pro-GRP、CA125和CEA与肺癌临床分期相关。CYFRA21-1、NSE和pro-GRP可用于监测化疗效果。
